HighTower Advisors
APLT

HighTower Advisors’s Applied Therapeutics APLT Stock Holding History

HighTower Advisors’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-220,001
Closed -$68.4K – 3827
2025
Q2 		$68.4K Buy
220,001
+100,000
+83% +$38.7K ﹤0.01% 3524
2025
Q1 		$58.7K Buy
+120,001
New +$70.7K ﹤0.01% 3435

Other funds holding APLT

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Pathstone Holdings
Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HighTower Advisors's APLT Position: Q3 2025 in Review

HighTower Advisors sold out of Applied Therapeutics (APLT) in Q3 2025, closing a stake of 220,001 shares — an estimated $68.4K sold.

HighTower Advisors first reported a position in APLT in Q1 2025 and held it in 2 quarters. The position peaked at $68.4K in Q2 2025. 70 funds tracked by Wall St. Rank hold APLT as of Q3 2025.

  • HighTower Advisors reported no remaining Applied Therapeutics position as of Q3 2025 after selling out during the quarter.
  • HighTower Advisors sold 220,001 Applied Therapeutics shares in Q3 2025, an estimated $68.4K.
  • HighTower Advisors first reported a position in Applied Therapeutics in Q1 2025 and held it in 2 quarters.
  • HighTower Advisors's Applied Therapeutics position peaked at $68.4K in Q2 2025.
  • 70 funds tracked by Wall St. Rank held Applied Therapeutics as of Q3 2025.

Based on HighTower Advisors's 13F filing for Q3 2025, filed 7 Nov 2025.